What is Gilteritinib? The role of treating leukemia

Gilteritinib is a new type of targeted small molecule tyrosine kinase inhibitor designed to inhibit signaling pathways related to FLT3 gene mutations. It is currently one of the first-line targeted drugs used to treat acute myeloid leukemia (AML). This drug is mainly targeted at patients with relapsed or refractory AML with FLT3 mutations (including ITD and TKD subtypes), and is an important achievement in the development of precision medicine. In the field of leukemia treatment, especially for patients who have poor response to traditional chemotherapy, giritinib provides a new drug approach to delay disease progression and improve quality of life.

Compared with traditional chemotherapy regimens, the biggest advantages of giritinib are its high selectivity and lower systemic toxicity. The drug can penetrate the cell membrane and precisely bind to the FLT3 mutant protein, thereby interfering with its kinase activity and terminating the proliferation and survival signals of tumor cells. Its oral administration method also greatly simplifies the treatment process, and is especially suitable for elderly patients or those with frail constitution who cannot tolerate high-intensity chemotherapy or bone marrow transplantation.

Currently, in many countries and regions, giritinib has become an important treatment option for relapsed and refractoryFLT3-positive AML, and research on its indications is gradually expanding. Although it may not be effective against all types of leukemia, the mechanism of targeting specific molecular targets makes it important in the trend of personalized treatment. Especially in patients with FLT3-ITD mutant AML who have a high relapse rate and poor prognosis, the role of giritinib provides hope for improving the remission rate and prolonging disease-free survival time.

Due to its unique targeting mechanism, giritinib is often included in combination treatment strategies and used in conjunction with other anti-tumor drugs or hematopoietic support treatments to form a multidimensional treatment plan. In the future, with the accumulation of more clinical studies, giritinib's positioning in the treatment of leukemia will continue to deepen, and it is expected to be expanded to be used in newly treated patients or as maintenance therapy.

Reference materials:https://www.xospata.com/